What does internal shivering without fever indicate in a patient with normal oxygen saturation, normal blood pressure, hypersensitivity to Aspergillus, recent exposure to the antigen, and progressive pulmonary fibrosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Likely Causes and Next Steps

Bold recommendation: Given your Aspergillus hypersensitivity with recent exposure and progressive pulmonary fibrosis, treat this as fibrotic hypersensitivity pneumonitis (HP) until proven otherwise, urgently eliminate exposure, and escalate ILD-directed care; ABPA therapy is not indicated unless you meet full ABPA criteria with asthma/bronchiectasis and active flare 1, 2.

  • What the “internal shivering” without fever likely means:
    • Autonomic adrenergic surge from respiratory irritation, air hunger, or anxiety; less likely sepsis given no fever, normal O2 and BP.
    • In the context of recent Aspergillus antigen exposure and progressive fibrosis, this symptom can signal ongoing antigen-driven HP inflammation rather than infection.

Decide between ABPA vs Hypersensitivity Pneumonitis (HP)

  • Prioritize HP if:
    • Progressive pulmonary fibrosis on HRCT, exposure to Aspergillus antigen, and no classic asthma/bronchiectasis-dominant picture. Fibrotic HP carries higher morbidity and mortality; exposure cessation is the single most impactful intervention for outcomes 1.
  • Consider ABPA only if ALL are present:
    • Predisposing condition (usually asthma/CF), Aspergillus-specific IgE positivity, total IgE ≥500 IU/mL, plus at least two of: Aspergillus-specific IgG, eosinophilia, or typical imaging (central bronchiectasis, mucus impaction, fleeting infiltrates). Treat acute ABPA with oral prednisolone or itraconazole; do not treat asymptomatic sensitization; avoid high-dose ICS or azoles as first-line without clear ABPA indication 2.

Action Algorithm (optimize morbidity, mortality, QoL)

  1. Immediate exposure control (today)

    • Remove from Aspergillus-rich environments (moldy spaces, compost, decaying vegetation, damp basements, humidifiers). Use HEPA filtration and professional remediation. This step has the strongest impact on halting HP progression and preserving lung function 1.

  2. Confirm the phenotype

    • Order: HRCT pattern review for fibrotic HP features; serum total IgE and A. fumigatus–specific IgE/IgG; blood eosinophils; bronchoalveolar lavage lymphocytosis if feasible; multidisciplinary ILD discussion per CHEST HP guideline to solidify HP diagnosis and exclude ABPA overlap 1.
    • If ABPA criteria are not met, do not start ABPA-directed steroids/azoles by default 2.

  3. Treat progressive pulmonary fibrosis (PPF) if criteria met

    • If your fibrosis is progressing (worsening symptoms, FVC/DLCO decline, or HRCT progression despite exposure avoidance), start antifibrotic therapy—nintedanib has supportive evidence in non-IPF PPF to slow decline and improve outcomes 3.
    • Continue strict exposure avoidance alongside antifibrotic therapy.

  4. Inflammatory control for HP

    • If subacute inflammatory HP activity is evident (BAL lymphocytosis, symptomatic inflammatory flares) despite exposure removal, consider a time-limited corticosteroid course; recognize that steroids relieve symptoms but do not change long-term fibrotic prognosis; prioritize antifibrotic if progression persists 1.

  5. Monitor and adjust

    • Every 8–12 weeks: symptoms, spirometry (FVC), DLCO, and HRCT if clinically indicated.
    • If ABPA criteria are later fulfilled with clinical flare, treat acute ABPA with either prednisolone (0.5 mg/kg/day tapered over ~4 months) or itraconazole monotherapy as per ISHAM 2024; combination only for recurrent exacerbations 2.

Pitfalls to avoid

  • Treating mere Aspergillus sensitization as ABPA without meeting criteria—leads to unnecessary steroids/azoles and worsened QoL 2.
  • Missing fibrotic HP due to “IPF” label—delays exposure removal and antifibrotic therapy, increasing mortality 1.
  • Assuming “shivering” implies infection—your normal vitals/O2 argue against sepsis; focus on antigen exposure and fibrotic progression.

When to seek urgent care

  • New hypoxemia, hemoptysis, rapid dyspnea escalation, or syncope. These increase mortality risk and need immediate evaluation.

In short: eliminate Aspergillus exposure now, classify your disease as fibrotic HP vs ABPA using guideline criteria, and if progression is confirmed, start antifibrotic therapy (nintedanib) to reduce decline; reserve ABPA therapy strictly for confirmed ABPA flares 1, 3, 2.

References

Related Questions

What is allergic bronchopulmonary aspergillosis (ABPA) and what work‑up and management are indicated for a patient with known Aspergillus hypersensitivity who was recently re‑exposed to mold and now presents only with internal shivering, normal oxygen saturation, and normal blood pressure?
What is the recommended management of allergic bronchopulmonary aspergillosis (ABPA)?
In a patient with idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern) who has completed treatment for active tuberculosis, are antifibrotic agents such as pirfenidone and nintedanib useful?
Can allergic bronchopulmonary aspergillosis cause wheezing?
With Aspergillus-specific IgE of 0.48 kU/L and Aspergillus-specific IgG of 56.8 U, how can I determine if the patient has allergic bronchopulmonary aspergillosis and what additional tests are required?
When does chronic coronary syndrome constitute a contraindication to strength training?
How should a dog bite be managed in a patient who has already completed a full rabies vaccination series?
How should rotator cuff syndrome be diagnosed and managed?
How should lenvatinib be initiated and managed in an adult patient with metastatic or locally advanced papillary thyroid carcinoma refractory to radioactive iodine?
In a patient with Aspergillus hypersensitivity, recent antigen exposure, normal oxygen saturation and blood pressure, and progressive pulmonary fibrosis, what decline in forced vital capacity (FVC) or diffusing capacity for carbon monoxide (DLCO) is considered significant?
How important is avoidance of the Aspergillus antigen in a patient with hypersensitivity pneumonitis and pulmonary fibrosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.